Abstract

NK1, a splicing variant of hepatocyte growth factor (HGF), binds to and activates Met receptor by forming an NK1 dimer and 2:2 complex with Met. Although the structural mechanism underlying Met activation by HGF remains incompletely resolved, it has been proposed that the NK1 dimer structure participates in this activation. We investigated the NK1 dimer interface’s role in Met activation by HGF. Because N127, V140, and K144 are closely involved in the head-to-tail NK1 dimer formation, mutant NK1 proteins with replacement of these residues by alanine were prepared. In Met tyrosine phosphorylation assays, N127-NK1, V140-NK1, and K144-NK1 showed 8.3%, 23.8%, and 52.2% activity, respectively, compared with wild-type NK1. Although wild-type NK1 promoted cell migration and scattering, N127-NK1, V140-NK1, and K144-NK1 hardly or marginally promoted them, indicating loss of activity of these mutant NK1 proteins to activate Met. In contrast, mutant HGFs (N127-HGF, V140-HGF, and K144-HGF) with the same amino acid replacements as in NK1 induced Met tyrosine phosphorylation and biological responses at levels comparable to those of wild-type HGF. These results indicate that the structural basis responsible for NK1-dependent Met dimer formation and activation differs from, or is at least distinguishable from, the structural basis responsible for HGF-dependent Met activation.

Highlights

  • In contrast to what had been believed for years, we reported that the Met-binding site in the K1 domain is dispensable for Met activation by hepatocyte growth factor (HGF), while the presence of the NK1 region is still required for Met activation [23]

  • The results indicate that NK1 dimer formation is indispensable for NK1-dependent Met activation, but unexpectedly it is dispensable in HGF-dependent Met activation

  • The individual amino acids that participate in NK1 dimer formation, N127, V140, and K144, were replaced with Ala (Figure 1C–E)

Read more

Summary

Introduction

Hepatocyte growth factor (HGF) and its receptor, the Met receptor tyrosine kinase, play important roles in embryonic development, tissue regeneration, and tumor progression [1,2,3]. Based on these physiological and pathogenic functions, HGF-Met signaling has been a target in drug discovery for both regeneration-based therapeutics and anticancer therapeutics [1,2,3]. The Met tyrosine kinase inhibitors capmatinib and tepotinib were approved in 2020 as anticancer drugs for the treatment of non-small cell lung cancer patients with Met exon 14 skipping [6,7]. An understanding of the structural basis explaining how HGF activates Met has remained elusive

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.